Preformulation of FK506 prodrugs for improving solubility = FK506 프로드럭의 용해도를 개선한 제형

Cited 3 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorY G Na-
dc.contributor.authorH S Jun-
dc.contributor.authorD Kim-
dc.contributor.authorByoung Chul Park-
dc.contributor.authorS K Lim-
dc.contributor.authorK H Lee-
dc.contributor.authorS J Hwang-
dc.contributor.authorJ S Park-
dc.contributor.authorS H Jung-
dc.contributor.authorC W Cho-
dc.date.accessioned2017-04-19T10:30:11Z-
dc.date.available2017-04-19T10:30:11Z-
dc.date.issued2016-
dc.identifier.issn0253-2964-
dc.identifier.uri10.1002/bkcs.10861ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/13551-
dc.description.abstractIn order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506-G or FK506-S) such as FK506-M32-LS-G (FK506-G) and FK506-M32-LS-SL (FK506-S) were synthesized. Two prodrugs (FK506-G or FK506-S), including FK506, were characterized by differential scanning calorimetry (DSC), X-ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506-G or FK506-S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506-S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506-G or FK506-S) in human plasma was evaluated by measuring the decrease of FK506-G or FK506-S as well as the increase of FK506 by HPLC, and FK506-G or FK506-S was metabolized in 1 h in human plasma. Two prodrugs (FK506-G or FK506-S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506-G, or 480.1 μg/mL for FK506-S against a conjunctive cell line, Clone 1-5c-4 cells. Taken together, FK506-S could be the most optimal prodrug for aqueous preparations based on preformulation data.-
dc.publisherWiley-
dc.titlePreformulation of FK506 prodrugs for improving solubility = FK506 프로드럭의 용해도를 개선한 제형-
dc.title.alternativePreformulation of FK506 prodrugs for improving solubility-
dc.typeArticle-
dc.citation.titleBulletin of Korean Chemical Society-
dc.citation.number0-
dc.citation.endPage1319-
dc.citation.startPage1313-
dc.citation.volume37-
dc.contributor.affiliatedAuthorByoung Chul Park-
dc.contributor.alternativeName나영국-
dc.contributor.alternativeName전혜석-
dc.contributor.alternativeName김대희-
dc.contributor.alternativeName박병철-
dc.contributor.alternativeName임시규-
dc.contributor.alternativeName이기호-
dc.contributor.alternativeName황성주-
dc.contributor.alternativeName박정숙-
dc.contributor.alternativeName정상훈-
dc.contributor.alternativeName조청원-
dc.identifier.bibliographicCitationBulletin of Korean Chemical Society, vol. 37, pp. 1313-1319-
dc.identifier.doi10.1002/bkcs.10861-
dc.subject.keywordCytotoxicity-
dc.subject.keywordFK506-
dc.subject.keywordPreformulation-
dc.subject.keywordProdrug-
dc.subject.keywordSolubility-
dc.subject.localCytotoxicity-
dc.subject.localcytotoxicity-
dc.subject.localFK506-
dc.subject.localPreformulation-
dc.subject.localProdrug-
dc.subject.localSolubility-
dc.subject.localsolubility-
dc.description.journalClassY-
Appears in Collections:
Critical Diseases Diagnostics Convergence Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.